Premium
Methotrexate therapy for autoimmune hearing loss: A preliminary report
Author(s) -
Sismanis Aristides,
Thompson Tab,
Willis Hayes E.
Publication year - 1994
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1288/00005537-199408000-00004
Subject(s) - methotrexate , medicine , rheumatoid arthritis , cyclophosphamide , hearing loss , adverse effect , sensorineural hearing loss , autoimmune disease , dermatology , immunology , chemotherapy , audiology , disease
The management of autoimmune sensorineural hearing loss (SNHL) continues to challenge the otologist. Steroids and cyclophosphamide, the two traditional medications for this malady, are often associated with serious adverse reactions. In an effort to use a less toxic medication, the authors treated five autoimmune SNHL patients with low‐dose oral methotrexate. Methotrexate has been found to be very effective in rheumatoid arthritis patients with acceptable adverse reactions. Preliminary results from this study indicate that methotrexate has the potential of being effective for autoimmune SNHL and associated otologic symptoms. Tolerance has been very good and side effects have been minimal.